The between a code that satisfies a payer and the information a physician needs to treat a person, is what nearly every healthcare AI tool is racing past. As we push these systems toward precision medicine and genomics, that gap stops being an annoyance and becomes a patient safety issue. The post The Code Gets…
[Sponsored] A new whitepaper by League highlights examples from collaborations with Baptist Health. The post Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations appeared first on MedCity News.
Amid an ongoing FDA re-review of mifepristone, awareness of the safety and prevalence of the abortion pill remains limited. This KFF poll also finds that the voters who say abortion policy is an important issue for 2026 midterm candidates to discuss are disproportionately Democrats.
One of America’s most competitive gubernatorial races could settle a heated argument over whether private insurance companies should run Medicaid. The race is in Iowa, whose Medicaid program has been plagued with controversy since 2016, when the state hired national insurance companies to manage billions of dollars’ worth of benefits. That shift was made by…
Over the past decade, Louisiana hospitals began stocking specialized carts designed to treat hemorrhages, one of the most common pregnancy complications in the state. The plug-in cart can be wheeled from room to room and holds surgical tools and lifesaving medications to stem blood loss. A state law passed in 2024 forced hospitals to remove…
The agency has not issued new research grants since April 2025, with 80% of staff departed, crippling its operational capacity
Doctronic acquired Summer Health to expand into pediatric care and strengthen its AI-powered primary care platform. The post Doctronic Acquires Summer Health to Expand into Pediatric Primary Care appeared first on MedCity News.
With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory validation from a recently approved Novartis drug. Vidya’s molecule is a next-generation drug that could have advantages over Novartis’s pill. The post Processa Acquisition Lands Immunology Drug That Could Rival…
A survey of 112 health system executives finds that Epic’s hold on hospital IT keeps getting stronger — but startups still have a shot, provided they solve a specific problem, prove strong ROI or offer a product that Epic is lagging behind on. The post Epic-First Doesn’t Mean Epic-Only: Where Hospitals Are Still Buying from…
The proposed rule extends payment limits to all SDPs and targeted FFS payments, potentially impacting provider reimbursement and care access